Danielle Brill
Stock Analyst at Truist Financial
(4.76)
# 629
Out of 4,966 analysts
405
Total ratings
55.2%
Success rate
15.8%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Reiterated: Buy | n/a | $70.06 | - | 21 | Sep 11, 2026 | |
| CLYM Climb Bio | Reiterated: Buy | n/a | $14.25 | - | 8 | Sep 4, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | n/a | $248.68 | - | 18 | Aug 31, 2026 | |
| SLDB Solid Biosciences | Initiated Coverage: Buy | $20 | $8.70 | +129.89% | 1 | Aug 21, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,030 → $1,095 | $984.39 | +11.24% | 34 | Aug 18, 2026 | |
| MAZE Maze Therapeutics | Reiterated: Buy | $64 | $24.79 | +158.22% | 5 | Aug 13, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $102 → $107 | $72.44 | +47.71% | 15 | Aug 12, 2026 | |
| UPB Upstream Bio | Reiterated: Buy | $43 → $25 | $5.70 | +338.60% | 7 | Aug 12, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | n/a | $515.44 | - | 10 | Aug 11, 2026 | |
| INSM Insmed | Reiterated: Buy | $195 | $129.41 | +50.68% | 10 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $29.05 | +106.54% | 12 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $30 | $37.36 | -19.70% | 15 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $616 | $334.58 | +84.11% | 3 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $128 | $106.20 | +20.53% | 9 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 | $43.62 | +28.38% | 3 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $29 → $34 | $41.25 | -17.58% | 20 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $207 | $150.13 | +37.88% | 13 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $213 | $156.22 | +36.35% | 24 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $235 | $217.15 | +8.22% | 19 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $4.59 | +226.80% | 3 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $9.19 | $44.51 | n/a | 23 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $8.53 | n/a | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $27.83 | n/a | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $33.60 | n/a | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $79 | $65.68 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $21.26 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $66.06 | n/a | 21 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $150 | $20.45 | n/a | 36 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $52 → $50 | $58.65 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.97 | n/a | 19 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 → $10 | $5.00 | n/a | 5 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $12.26 | n/a | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $45 | $11.16 | n/a | 2 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $45.87 | n/a | 10 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $220.75 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $5 | $19.62 | n/a | 5 | Nov 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $143.72 | n/a | 1 | Jul 26, 2016 |
Disc Medicine
Sep 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $70.06
Upside: -
Climb Bio
Sep 4, 2026
Reiterated: Buy
Price Target: n/a
Current: $14.25
Upside: -
Alnylam Pharmaceuticals
Aug 31, 2026
Reiterated: Buy
Price Target: n/a
Current: $248.68
Upside: -
Solid Biosciences
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $8.70
Upside: +129.89%
argenx SE
Aug 18, 2026
Reiterated: Buy
Price Target: $1,030 → $1,095
Current: $984.39
Upside: +11.24%
Maze Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $64
Current: $24.79
Upside: +158.22%
BridgeBio Pharma
Aug 12, 2026
Reiterated: Buy
Price Target: $102 → $107
Current: $72.44
Upside: +47.71%
Upstream Bio
Aug 12, 2026
Reiterated: Buy
Price Target: $43 → $25
Current: $5.70
Upside: +338.60%
Vertex Pharmaceuticals
Aug 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $515.44
Upside: -
Insmed
Aug 10, 2026
Reiterated: Buy
Price Target: $195
Current: $129.41
Upside: +50.68%
Aug 10, 2026
Reiterated: Buy
Price Target: $60
Current: $29.05
Upside: +106.54%
Aug 7, 2026
Reiterated: Hold
Price Target: $30
Current: $37.36
Upside: -19.70%
Aug 7, 2026
Reiterated: Buy
Price Target: $616
Current: $334.58
Upside: +84.11%
Aug 6, 2026
Reiterated: Buy
Price Target: $128
Current: $106.20
Upside: +20.53%
Aug 6, 2026
Reiterated: Buy
Price Target: $56
Current: $43.62
Upside: +28.38%
Aug 5, 2026
Reiterated: Hold
Price Target: $29 → $34
Current: $41.25
Upside: -17.58%
Aug 5, 2026
Reiterated: Buy
Price Target: $207
Current: $150.13
Upside: +37.88%
Aug 3, 2026
Reiterated: Buy
Price Target: $200 → $213
Current: $156.22
Upside: +36.35%
Jul 31, 2026
Reiterated: Buy
Price Target: $235
Current: $217.15
Upside: +8.22%
Jul 31, 2026
Reiterated: Buy
Price Target: $15
Current: $4.59
Upside: +226.80%
Dec 10, 2024
Reiterated: Buy
Price Target: $20 → $9.19
Current: $44.51
Upside: n/a
Nov 18, 2024
Reiterated: Buy
Price Target: $18
Current: $8.53
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $27.83
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $33.60
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $79
Current: $65.68
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $21.26
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $66.06
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $150
Current: $20.45
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $52 → $50
Current: $58.65
Upside: n/a
Jun 26, 2023
Downgraded: Hold
Price Target: n/a
Current: $7.97
Upside: n/a
May 16, 2022
Reiterated: Buy
Price Target: $24 → $10
Current: $5.00
Upside: n/a
Jun 30, 2021
Initiated Coverage: Hold
Price Target: n/a
Current: $12.26
Upside: n/a
May 27, 2020
Reiterated: Buy
Price Target: $35 → $45
Current: $11.16
Upside: n/a
Feb 13, 2020
Reiterated: Hold
Price Target: n/a
Current: $45.87
Upside: n/a
Dec 16, 2019
Reiterated: Buy
Price Target: $125
Current: $220.75
Upside: n/a
Nov 7, 2019
Reiterated: Hold
Price Target: $6 → $5
Current: $19.62
Upside: n/a
Jul 26, 2016
Downgraded: Hold
Price Target: n/a
Current: $143.72
Upside: n/a